JLE

European Journal of Dermatology

MENU

Pegylated interferon-α2b for local control of Langerhans cell sarcoma Volume 28, numéro 6, November-December 2018

Illustrations


  • Figure 1
Auteurs
Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Langerhans cell histiocytosis (LCH) is a disease in which cells with features of epidermal Langerhans cells (LCs) accumulate in the skin and/or other organs [1, 2]. Although such skin lesions can affect patients’ quality of life [3], there is a paucity of evidence for effective treatments [1]. Here, we report a patient with Langerhans cell sarcoma (LCS), a highly malignant form of LCH [4], in whom pegylated interferon (PEG-IFN)-α2b was effective for the management of skin lesions.A 58-year-old Japanese [...]